PhagoMed’s endolycin therapy for vaginosis wins accolades in EU

December 6, 2020 0 By FM

PhagoMed Biopharma GmbH came 2nd and won € 20.000 in the Health Catapult of the European Institute of Innovation and Technology (EIT).

The company´s synthetic lysin platform with bacterial vaginosis as a first target indication was selected by an international jury as a leading biotech innovation in Europe in 2020.

PhagoMed’s lead programme is an engineered phage endolysin that offers an innovative therapy for recurrent bacterial vaginosis, a disease for which no effective treatment option exists.

Recently, PhagoMed released data showing that their drug candidate not only lyses the bacterial strain mainly responsible for the infection, but also fully dissolves resistant biofilms. Furthermore, due to the high specificity of the endolysin, the beneficial microbiome remained unharmed. This combination of high efficacy and high precision makes the endolysin a highly innovative solution for recurrent bacterial vaginosis, which affects 100 million women every year.

The EIT Health Catapult is a year-long multistage challenge designed to identify and accelerate promising European start-ups in the categories of Biotech, Medtech and Digital Health.

The international contest started in May and comprised several levels of competition. During the final stage in December one winner and two runner-up were chosen from 7 finalists in the biotech category. During the contest each team pitched their solution to the EIT Health network, one of the largest healthcare communities worldwide including over 150 leading healthcare organisations.

PhagoMed was selected at the regional final in May 2020 where it competed against finalists from Germany, Switzerland and Austria. In the semi-finals in October the company was not only selected for the December finals but was also awarded the LallianSe price for most exciting market access opportunity. The 2nd place of the overall competition the company now reached comes with an award of € 20.000 and is a strong sign of the resurgence of interest in novel anti-bacterials and in PhagoMed’s lead programme in recurrent bacterial vaginosis, according to a statement.